

AMENDMENTS TO THE CLAIMS

1-16. (cancelled)

17. (new) An isolated antibody that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2.

18. (new) An isolated antibody that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide comprises SEQ ID NO:2.

19. (new) The antibody of claim 17, wherein the antibody is a monoclonal antibody.

20. (new) The antibody of claim 18, wherein the antibody is a monoclonal antibody.

21. (new) The antibody of claim 17, wherein the antibody is coupled to a detectable substance.

22. (new) The antibody of claim 18, wherein the antibody is coupled to a detectable substance.

23. (new) The antibody of claim 19, wherein the antibody is coupled to a detectable substance.

24. (new) The antibody of claim 20, wherein the antibody is coupled to a detectable substance.

BEST AVAILABLE COPY

25. (new) A composition comprising the antibody of claim 17 and a pharmaceutically acceptable carrier.
26. (new) A composition comprising the antibody of claim 18 and a pharmaceutically acceptable carrier.
27. (new) A composition comprising the antibody of claim 19 and a pharmaceutically acceptable carrier.
28. (new) A composition comprising the antibody of claim 20 and a pharmaceutically acceptable carrier.
29. (new) An isolated antibody fragment that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2, and wherein the antibody fragment comprises a fragment selected from the group consisting of:
 - a) an Fab fragment;
 - b) an F(ab')₂ fragment; and
 - c) an Fv fragment.
30. (new) An isolated antibody fragment that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide comprises SEQ ID NO:2, and wherein the antibody fragment comprises a fragment selected from the group consisting of:
 - a) an Fab fragment;
 - b) an F(ab')₂ fragment; and
 - c) an Fv fragment.